You are viewing a preview of...
Gastrointestinal (GI) Locally-Activating JAK Inhibitor for Treatment of Ulcerative Colitis
A novel JAK inhibitor that successfully treats ulcerative colitis with minimal systemic absorption and therefore low risk of side effects
Background
Inflammatory Bowel Disease (IBD) affects about one million people in the United States. The major types of inflammatory bowel disease (IBD) are ulcerative colitis (UC) and Crohn’s disease, with the incidence of the former twice that of the latter. UC usually originates the rectum and extends proximally to the colon. The associated inflammation is restricted to the innermost, or mucosal, layer of the intestine and results in ulceration and bloody diarrhea. In addition, UC patients have up to 18% higher risk of developing colon cancer, depending on the severity and the duration of the disease. UC occurs widely in all age groups and large portion of patients relapse, thereby requiring life-long treatment.
Several treatment options exist for patients with
Log in or create a free account to continue reading